|
| 37558543 | Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer. | Eur Urol Oncol | 2024 |
| 36564933 | A correlative biomarker study and integrative prognostic model in chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide. | Prostate | 2023 |
| 37507278 | The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer. | Clin Oncol (R Coll Radiol) | 2023 |
| 37060201 | A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. | Cancer | 2023 |
| 36952634 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37285866 | Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer. | Lancet | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37399894 | Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. | Ann Oncol | 2023 |
| 37164128 | Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer. | Ann Oncol | 2023 |
| 36870853 | Transcriptomic Heterogeneity in High-risk Prostate Cancer and Implications for Extraprostatic Disease at Presentation on Prostate-specific Membrane Antigen Positron Emission Tomography. | Eur Urol Oncol | 2023 |
| 36798177 | Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial. | Res Sq | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34605002 | Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patients. | Int J Cancer | 2022 |
| 35809752 | ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. | Ann Oncol | 2022 |
| 35653395 | Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. | PLoS One | 2022 |
| 35411939 | Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). | Int J Cancer | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35671327 | Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. | PLoS Med | 2022 |
| 35715640 | Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. | Br J Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 36265504 | Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study. | Lancet Oncol | 2022 |
| 36059000 | Accumulation of copy number alterations and clinical progression across advanced prostate cancer. | Genome Med | 2022 |
| 36321266 | Accidentals of the DNA Symphony. | Cancer Res | 2022 |
| 35877084 | Docetaxel for Nonmetastatic Prostate Cancer: Long-Term Survival Outcomes in the STAMPEDE Randomized Controlled Trial. | JNCI Cancer Spectr | 2022 |
| 35013522 | Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. | Prostate Cancer Prostatic Dis | 2022 |
| 35202397 | The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses. | PLoS One | 2022 |
| 34757812 | Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. | J Clin Oncol | 2022 |
| 34844839 | Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. | Eur J Cancer | 2022 |
| 33373705 | Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. | Urology | 2021 |
| 33794293 | Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. | Ann Oncol | 2021 |
| 33599706 | Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 33570548 | Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer: An Ancillary Study of the NRG/RTOG 9601 Randomized Clinical Trial. | JAMA Oncol | 2021 |
| 34870187 | The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer. | Front Artif Intell | 2021 |
| 34789334 | ReIMAGINE: a prostate cancer research consortium with added value through its patient and public involvement and engagement. | Res Involv Engagem | 2021 |
| 34489465 | Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. | Nat Commun | 2021 |
| 34600602 | Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. | Lancet Oncol | 2021 |
| 34077818 | Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. | Eur J Cancer | 2021 |
| 34274134 | Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. | Eur Urol | 2021 |
| 34129855 | Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial. | Ann Oncol | 2021 |
| 34112710 | Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. | Clin Cancer Res | 2021 |
| 34333554 | Circulating androgen receptor gene amplification and resistance to <sup>177</sup>Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. | Br J Cancer | 2021 |
| 33436326 | Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. | Eur Urol Oncol | 2021 |
| 32149736 | Genome-wide plasma DNA methylation features of metastatic prostate cancer. | J Clin Invest | 2020 |
| 33854564 | Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phaseâ¿¿II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK - A16037). | Ther Adv Med Oncol | 2020 |
| 35050761 | Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. | JCO Precis Oncol | 2020 |
| 32001144 | Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. | Eur Urol | 2020 |
| 31922552 | ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. | Bioinformatics | 2020 |
| 32067690 | Corrigendum to Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial: Ann Oncol 2019; 30: 1992-2003. | Ann Oncol | 2020 |
| 32591246 | The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDE's "M1|RT Comparison". | Eur Urol Oncol | 2020 |
| 32669676 | Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. | Br J Cancer | 2020 |